DKSH Business Unit Healthcare has signed an agreement to acquire Acutest Systems, a Malaysian in-vitro diagnostic provider, expanding its presence in the fragmented medical device industry in Asia Pacific. The closing of the transaction is expected during the second quarter of 2022 and is subject to certain conditions.
The transaction diversifies DKSH’s medical device business and provides the company access to additional general practitioners, pharmacy chains, medical centers, laboratories and hospitals. Malaysia is a dynamic medical device market which offers significant growth opportunities. Acutest also has a solid customer base and complementary supplier and product portfolios.
According to the LevinProHC database, this marks the 52nd Medical Devices deal since the start of 2022, as well as the 16th announced during the month of May, so far. The largest acquirer in the space has been ArchiMed, which acquired Natus Medical Incorporated in April for $1.2 billion.
Founded in the 1980s, Acutest Systems is a distributor of clinical diagnostic point-of-care testing analyzers, diagnostic and screening devices and instruments and laboratory systems in Malaysia. The company employs around 25 people and recorded net sales of over CHF 3 million in 2021, or approximately $3.12 million.
DKSH is a Swiss holding company specializing in market expansion services, with a focus on Asia. The DKSH Business Unit Healthcare distributes pharmaceuticals, consumer health and over-the-counter products as well as medical devices. With around 7,290 specialists, the business unit generated net sales of CHF 5.6 billion in 2021, or approximately $5.824 billion.
